PTC Therapeutics Quarterly Income Statement
NASDAQ: PTCTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
PTC Therapeutics revenue and earnings
In the quarter ended Jun 30, 2026, PTC Therapeutics generated $360.5 million in revenue, up 101.5% from the same quarter a year earlier. Net income was $83.5 million, for a net margin of 23.2% versus a median of -1.0% in the prior 5 quarters. Operating margin was 41.3%.
Diluted earnings per share came in at $0.92.
Summary generated from market data by MetaCap's automated system. Methodology
PTC Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 360.52M | 272.55M | 164.68M | 211.01M | 178.88M | 1.18B | 213.17M | 196.79M | 186.70M | 210.12M | 307.06M | 196.58M |
| Revenue growth (YoY) | +101.55% | -76.83% | -22.75% | +7.23% | -4.19% | +459.73% | -30.58% | +0.11% | -12.68% | -4.66% | +83.41% | -9.46% |
| Operating Expenses | 211.54M | 227.59M | 236.03M | 207.99M | 213.83M | 205.87M | 375.56M | 251.30M | 226.92M | 255.57M | 301.24M | 314.74M |
| Research & Development | 99.15M | 100.87M | 133.13M | 100.16M | 112.99M | 108.97M | 124.77M | 161.41M | 132.17M | 116.13M | 121.35M | 164.21M |
| Selling, General & Admin | 80.63M | 86.18M | 96.87M | 84.05M | 85.26M | 80.96M | 84.68M | 73.46M | 69.50M | 73.27M | 76.29M | 80.89M |
| Operating Income | 148.98M | 44.96M | -71.35M | 3.02M | -34.96M | 970.23M | -162.39M | -54.51M | -40.22M | -45.45M | 5.82M | -118.16M |
| Other Income (Expense) | -2.95M | 1.61M | -12.55M | 6.50M | -5.74M | -6.30M | 8.85M | -1.87M | -2.02M | 1.59M | 18.96M | -20.27M |
| Pretax Income | 97.55M | -2.46M | -139.08M | -23.07M | -71.05M | 929.83M | -94.70M | -97.99M | -85.73M | -84.70M | -157.05M | -166.59M |
| Income Tax | 14.05M | 347.00K | -4.12M | -38.97M | -6.20M | 63.27M | -28.81M | 8.66M | 13.45M | 6.88M | -1.26M | -33.62M |
| Net Income | 83.50M | -2.81M | -134.97M | 15.90M | -64.85M | 866.56M | -65.89M | -106.65M | -99.18M | -91.58M | -155.79M | -132.97M |
| Net Income growth (YoY) | — | -100.32% | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | 1.01 | -0.03 | -1.88 | 0.20 | -0.83 | 11.09 | -0.85 | -1.39 | -1.29 | -1.20 | -2.07 | -1.76 |
| EPS (Diluted) | 0.92 | -0.03 | -1.63 | 0.20 | -0.83 | 10.04 | -0.85 | -1.39 | -1.29 | -1.20 | -2.07 | -1.76 |
| Shares Outstanding (Basic) | 83.01M | 82.52M | — | 78.47M | 78.15M | 78.12M | — | 76.93M | 76.73M | 76.50M | — | 75.38M |
| Shares Outstanding (Diluted) | 92.02M | 82.52M | — | 87.12M | 78.15M | 86.39M | — | 76.93M | 76.73M | 76.50M | — | 75.38M |
| EBITDA | 164.85M | 60.37M | -58.45M | 14.13M | -27.37M | 977.45M | -155.63M | -48.02M | -33.20M | 9.94M | 86.53M | -56.11M |
| Operating Margin | 41.32% | 16.50% | -43.33% | 143.00% | -19.54% | 82.50% | -76.18% | -27.70% | -21.54% | -21.63% | 1.90% | -60.11% |
| Net Margin | 23.16% | -103.00% | -81.96% | 7.53% | -36.25% | 73.68% | -30.91% | -54.20% | -53.12% | -43.58% | -50.74% | -67.64% |
This table shows 12 quarterly periods of PTC Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow PTCT's reporting calendar. What is a income statement?